Alirocumab (ALI) Compassionate Use Program Providing Early Access to Alirocumab (ALI) Prior to its Commercial Availability to Patients with Severe Heterozygous Familial Hypercholesterolaemia and/or High-Risk Patients (LDL-C ≥160 mg/dL ) Not Controlled with Maximal Tolerated Dose (MTD) of Standard of Care Lipid-Lowering Therapy (LLT)

Trial Profile

Alirocumab (ALI) Compassionate Use Program Providing Early Access to Alirocumab (ALI) Prior to its Commercial Availability to Patients with Severe Heterozygous Familial Hypercholesterolaemia and/or High-Risk Patients (LDL-C ≥160 mg/dL ) Not Controlled with Maximal Tolerated Dose (MTD) of Standard of Care Lipid-Lowering Therapy (LLT)

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 17 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top